Lung cancer is a leading cause of cancer death in the United States and worldwide. One of the recent breakthroughs in lung cancer treatment was the discovery of the somatic activating mutations of the epidermal growth factor receptor (EGFR) tyrosine kinase domain in non-small cell lung cancer (NSCLC), which is associated with a dramatic clinical response to EGFR inhibitors such as gefitinib and erlotinib. Erlotinib is particularly effective in patients with EGFR mutations. However, most patients with initial responses to erlotinib treatment eventually relapse due to acquired resistance to erlotinib. The purpose of this proposal is to analyze chronological changes in tumor size and volume in advanced NSCLC patients treated with erlotinib in clinical trials at Dana-Farber Cancer Institute, and determine if the tumor volume detects relapse caused by acquired resistance earlier than the tumor size does. If this is proven, tumor volume can be used as the primary marker for monitoring response to therapy instead of the conventional marker, tumor size. Early detection of acquired resistance to erlotinib by tumor volume analysis will allow oncologists to change therapeutic regimen for prolongation of progression-free survival. We also aim to determine if the initial proportional decreases in tumor size and volume correlate with progression-free survival and overall survival of the patients. If this is the case, tumor volume measured by CT can be used as a biomarker for prognosis. We will also determine if the tumor size and volume changes correlate with genomic changes in circulating tumor cells and free plasma DNA in advanced NSCLC patients. Genomic analysis of circulating tumor cells and free plasma DNA in NSCLC is an emerging non-invasive technique which allows for frequent assessment of genomic changes during therapy. The study will be performed using data collected in phase II prospective clinical trials of erlotinib in advanced NSCLC patients at the Dana-Farber Cancer Institute. Data includes chest CT examinations performed every eight weeks and EGFR mutation analysis. Tumor size and volume will be measured using a commercially available, Food and Drug Administration (FDA) approved volume analysis software. Changes of tumor size and volume will be calculated, and will be correlated with clinical outcome and genomic analysis results. The long term goal of the project is to determine the imaging parameters that most efficiently predict acquired resistance to erlotinib by integrating the genomic information into the tumor volume analysis, in order to optimize the therapeutic benefit of erlotinib and contribute to the prolongation of survival in lung cancer patients.
Lung cancer is a leading cause of cancer death in the United States and worldwide needing more effective treatment options. The epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, has emerged as an attractive therapy for non-small cell lung cancer with a dramatic clinical response;however, most patients with initial responses eventually relapse due to acquired resistance. We aim to perform detailed chronological analysis of tumor size and volume in correlation with genomic information obtained from biopsy specimens, circulating tumor cells, and plasma DNA in lung cancer patients treated with erlotinib for early detection of resistance to erlotinib and prolongation of survival.
|Cooley, Christine; Nishino, Mizuki; Jagannathan, Jyothi et al. (2014) Clinical problem solving: utility of sonography in oncologic patients. J Ultrasound Med 33:9-22|
|Nishino, M; Jackman, D M; DiPiro, P J et al. (2014) Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy. Clin Radiol 69:841-8|
|Araki, T; Sholl, L M; Gerbaudo, V H et al. (2014) Intrathymic cyst: clinical and radiological features in surgically resected cases. Clin Radiol 69:732-8|
|Araki, Tetsuro; Sholl, Lynette M; Gerbaudo, Victor H et al. (2014) Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia. AJR Am J Roentgenol 202:471-8|
|Nishino, Mizuki; Itoh, Harumi; Hatabu, Hiroto (2014) A practical approach to high-resolution CT of diffuse lung disease. Eur J Radiol 83:6-19|
|Krajewski, Katherine M; Nishino, Mizuki; Franchetti, Yoko et al. (2014) Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 120:711-21|
|Araki, Tetsuro; Sholl, Lynette M; Gerbaudo, Victor H et al. (2014) Thymic measurements in pathologically proven normal thymus and thymic hyperplasia: intraobserver and interobserver variabilities. Acad Radiol 21:733-42|
|Kim, Kyung Won; Krajewski, Katherine M; Jagannathan, Jyothi P et al. (2013) Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know. AJR Am J Roentgenol 200:484-92|
|Nishino, Mizuki; Cardarella, Stephanie; Dahlberg, Suzanne E et al. (2013) Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 79:283-8|
|Nishino, Mizuki; Dahlberg, Suzanne E; Cardarella, Stephanie et al. (2013) Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 119:3761-8|
Showing the most recent 10 out of 19 publications